- Home
- MYGN vs BLTE Comparison
MYGN vs BLTE Comparison
Compare MYGN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BLTE
- Stock Information
- Founded
- MYGN 1991
- BLTE 2018
- Country
- MYGN United States
- BLTE United States
- Employees
- MYGN N/A
- BLTE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- BLTE Health Care
- Exchange
- MYGN Nasdaq
- BLTE Nasdaq
- Market Cap
- MYGN 2.0B
- BLTE 2.1B
- IPO Year
- MYGN 1995
- BLTE 2022
- Fundamental
- Price
- MYGN $15.25
- BLTE $82.81
- Analyst Decision
- MYGN Buy
- BLTE Strong Buy
- Analyst Count
- MYGN 12
- BLTE 4
- Target Price
- MYGN $27.64
- BLTE $89.00
- AVG Volume (30 Days)
- MYGN 990.7K
- BLTE 110.7K
- Earning Date
- MYGN 11-07-2024
- BLTE 11-12-2024
- Dividend Yield
- MYGN N/A
- BLTE N/A
- EPS Growth
- MYGN N/A
- BLTE N/A
- EPS
- MYGN N/A
- BLTE N/A
- Revenue
- MYGN $823,600,000.00
- BLTE N/A
- Revenue This Year
- MYGN $13.85
- BLTE N/A
- Revenue Next Year
- MYGN $7.73
- BLTE N/A
- P/E Ratio
- MYGN N/A
- BLTE N/A
- Revenue Growth
- MYGN 12.15
- BLTE N/A
- 52 Week Low
- MYGN $15.18
- BLTE $31.01
- 52 Week High
- MYGN $29.30
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- MYGN 16.18
- BLTE 73.39
- Support Level
- MYGN $16.86
- BLTE $77.62
- Resistance Level
- MYGN $19.60
- BLTE $86.53
- Average True Range (ATR)
- MYGN 1.17
- BLTE 5.84
- MACD
- MYGN -0.25
- BLTE 0.69
- Stochastic Oscillator
- MYGN 0.90
- BLTE 88.01
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.